Home » EU Approves Jazz’ Vyxeos for Certain Forms of Acute Myeloid Leukemia
EU Approves Jazz’ Vyxeos for Certain Forms of Acute Myeloid Leukemia
August 30, 2018
The European Commission approved Jazz’s Vyxeos for treating adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
An advanced liposomal formulation, Vyxeos delivers a synergized combination of daunorubicin and cytarabine to slow tumor growth and kill cancer cells.
AML is a form of blood cancer that begins growth in bone marrow, crowding out healthy cells to spread cancer throughout the body via the bloodstream.
Upcoming Events
-
21Oct